Tetrazolylpropionamides as inhibitors of Aβ protein...

Details Tetrazolylpropionamides as inhibitors of Aβ protein... Tetrazolylpropionamides as inhibitors of Aβ protein...

2006-02-21

2006-02-21

Richter, Johann (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S326000, C514S381000, C540S491000, C540S603000, C546S210000, C548S252000

Reexamination Certificate

active

07001901

ABSTRACT:
This invention relates to novel tetrazolyl-propionamides in which the amide group comprises an aminoazepinone, and related structures, of Formula (I):or pharmaceutically acceptable salt or prodrug forms thereof, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby resulting in prevention and treatment of the neuropathology associated with production of Aβ-peptide. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease.

REFERENCES:
patent: WO 00/07995 (2000-02-01), None
patent: WO 00/38618 (2000-07-01), None
patent: WO 01/77086 (2001-10-01), None
patent: WO 01/92235 (2001-12-01), None
Chapman, P. F., et al., “Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice”,Nature Neurosci.(1999), 2, 271-276.
Dahlgren, K. N., et al., “Oligomeric and Fibrillar Species of Amyloid-β Peptides Differentially Affect Neuronal Viability”,J. Biol. Chem.(2002), 277, 32046-32053.
Götz, J., et al., “Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by Aβ42 Fibrils”,Science(2001) 293, 1491-1495.
Lewis, J., et al., “Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP”,Science(2001), 293, 1487-1491.
McLean, C. A., et al., “Soluble pool of Aβ-amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease”,Ann. Neurol.(1999) 46, 860-866.
Seiffert, D.,F., et al., “Presenilin-1 and -2 Are Molecular Targets for γ-Secretase Inhibitors”,J. Biol. Chem.(2000) 275, 34086-34091.
Selkoe, D. J., “Alzheimer's Disease: Genes, Proteins, & Therapy”,Physiol. Rev.(2001) 81, 741-766.
Selkoe, D. J., “ . . . Mechanism of Alzheimer's Disease”,Ann. Rev. Cell Biol.(1994) 10:373-403.
Thal, D. R., et al., “Two Types of Sporadic Cerebral Amyloid Angiopathy”,J. Neuropath. Exp. Neuro.(2002) 61: 82-293.
Walsh, D. M., et al., “Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo”,Nature(2002) 416, 535-539.
Wolfe, M. S., “Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential”,J. Med. Chem.(2001) 44, 2039-2060.

Affiliated with

Also associated with

Rating

Tetrazolylpropionamides as inhibitors of Aβ protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Tetrazolylpropionamides as inhibitors of Aβ protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tetrazolylpropionamides as inhibitors of Aβ protein... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3630858